<qa>  What is the phase II phase of the study?Aims - The phase II stage of the study aims to determine the relative toxicity of the combination of capecitabine and bevacizumab and the combination of capecitabine, mitomycin C MMC and bevacizumab with that of capecitabine monotherapy and to assess tumour response rate RECIST criteria for each arm 